BlueRock Therapeutics was founded in 2016 when Versant Ventures, a top-tier venture capital firm, and global pharmaceutical giant Bayer AG provided $225 million in one of the largest-ever Series A financings in biotech history.Driven by a mission to develop regenerative medicines for intractable diseases, and initially focusing on the work of two McEwen Stem Cell Institute Scientists, BlueRock Therapeutics is advancing a novel Cell+Gene platform to develop, manufacture and deliver cell-based therapies.
The work of Dr. Gordon Keller and Dr. Michael Laflamme is part of BlueRock's first efforts to commercialize an approach to regenerating heart muscle in patients who have had a heart attack or suffer from chronic heart failure. The potential of cell therapy for regenerative medicines has been recognized for decades. However, the complexity of manufacturing cells that are suitable for use in patients at clinical scale has hindered development — until now. Using the latest in molecular biology technologies and manufacturing approaches, BlueRock is poised to overcome these hurdles.
Learn more about
BlueRock Therapeutics »
CCRM is a Canadian, not-for-profit funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners. It supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. CCRM has a 40,000 square foot space dedicated to advanced cell manufacturing that includes a fully resourced development facility used to both evaluate and advance technologies. CCRM aims to accelerate the translation of scientific discovery into new companies and marketable products for patients. CCRM is the commercialization partner of OIRM and University of Toronto’s
Medicine by Design.
Learn more about
CCRM »
UHN and the Technion-Israel Institute of Technology have established a new Centre aimed at developing new ways to treat heart disease. By combining the efforts of the leading scientists and clinicians of Technion and UHN, this partnership, which includes UHN's McEwen Centre for Regenerative Medicine and the Peter Munk Cardiac Centre, will develop new cardiovascular devices and regenerative medicine therapies and innovations that will benefit not only Canadians and Israel but all patients suffering from cardiovascular disease across the globe. Moreover, the new Centre will support the training of the next generation of scientists and clinicians who will specialize in the continually growing fields of stem cell and regenerative medicine research.
Learn more about
Technion »
